A similar meta-analysis, which included 68,653 patients across 10 trials, found that while GLP-1 receptor agonists did not reduce the risk of hospitalization for HF, they may offer potential benefits in patients without a prior history of HF. The gene discussed is GLP1R; the disease is hydrops fetalis.